ArticleOncogene2008
Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
Article in Oncogene, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 330 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
330 citing papers in PubMed, 2 syntheses or guidelines pooled it, 605 citations in OpenAlex.
- Prognostic significance of EZH2 expression in patients with oesophageal cancer: a meta-analysis.Journal of cellular and molecular medicine · 2016Pooled it
- Prognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis.Scientific reports · 2016Pooled it
- Trial
- MEF2A nuclear translocation mediated by ROCK phosphorylation promotes EZH2 expression and peritoneal fibrosis.Renal failure · 2026Article
- Review
- Noncanonical EZH2 activity cooperates with FOXM1 to drive tumorigenesis and advanced progression in HCC.Clinical and molecular hepatology · 2026Article
- EZH2 directs HER2+ breast cancer progression through the modulation of epithelial plasticity.EMBO reports · 2026Article
- Article
- Identification of 5mC regulatory factors mediating methylation patterns and prognosis models in head and neck squamous cell carcinoma.Discover oncology · 2025Article
- Review
- Anoikis resistance in Cancer: Mechanisms, therapeutic strategies, potential targets, and models for enhanced understanding.Cancer letters · 2025Review
- NASP implication in the androgen receptor associated with castration resistance in prostate cancer.Cell communication and signaling : CCS · 2025Article
- Polycomb repressive complex 2 (PRC2) pathway's role in cancer cell plasticity and drug resistance.Functional & integrative genomics · 2025Review
- NSD3 protein methylation and stabilization transforms human ES cells into variant state.Life science alliance · 2025Article
- CBX2 suppresses interferon signaling to diminish tumor immunogenicity via a noncanonical corepressor complex.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Stage-dependent EZH2 methylation correlates with immune polarization, metabolic suppression, and unfavorable outcomes in hepatocellular carcinoma.International journal of medical sciences · 2025Article
- Integration of epigenomic and transcriptomic profiling uncovers EZH2 target genes linked to cysteine metabolism in hepatocellular carcinoma.Cell death & disease · 2024Article
- EZH2 inhibition or genetic ablation suppresses cyst growth in autosomal dominant polycystic kidney disease.Journal of translational medicine · 2024Article
- Review
- Computed tomography-based radiomics predicts the fibroblast-related geneWorld journal of clinical cases · 2024Article
270 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
Enhancer of zeste homolog 2 (EZH2) is a critical component of the polycomb-repressive complex 2 (PRC2), which is involved in gene silencing and histone H3 lysine 27 methylation. EZH2 has a master regulatory function in controlling such processes as stem cell differentiation, cell proliferation, early embryogenesis and X chromosome inactivation. Although benign epithelial cells express very low levels of EZH2, increased levels of EZH2 have been observed in aggressive solid tumors such as those of the prostate, breast and bladder. The mechanism by which EZH2 mediates tumor aggressiveness is unclear. Here, we demonstrate that EZH2 mediates transcriptional silencing of the tumor suppressor gene E-cadherin by trimethylation of H3 lysine 27. Histone deacetylase inhibitors can prevent EZH2-mediated repression of E-cadherin and attenuate cell invasion, suggesting a possible mechanism that may be useful for the development of therapeutic treatments. Taken together, these observations provide a novel mechanism of E-cadherin regulation and establish a functional link between dysregulation of EZH2 and repression of E-cadherin during cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.